The nation of Zimbabwe has turned down a major American health deal valued at 367 million US dollars (£272m) spanning five years because of Washington's insistence on confidential biological samples.
This rejection was revealed following a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesperson has since clarified that the US was requesting health data for research and commercial gain while was not willing to guarantee the resulting advantages from any future vaccines.
"We are forced to start the challenging and unfortunate process of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had donated more than $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for further dialogue to reach a agreement acceptable to both sides so the country's vital HIV programme can continue.
Broader Context
This development follows a comparable case in neighbouring Kenya, where a high court halted a similar health funding agreement after concerns were filed about the security of citizens' health data.
After resuming office last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
The agency had managed aid for the American government, but Trump argued its spending was "wasteful" and his administration was pursuing direct bilateral deals to enhance transparency and accountability.
As per reports, 16 African countries have to date agreed to similar health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The money for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation might have yielded significant advantages for the people of Zimbabwe, particularly the 1.2 million currently on HIV treatment via American-funded programmes," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no corresponding promise of access to any medical innovations – like new medicines or tests – that could be developed from that shared data," he stated.
"In essence, our country would supply the basic resources for scientific discovery without any assurance that the resulting innovations would be available to our population should a new pandemic arise."
National Interest and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were undermining frameworks already set up through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system designed to deal with potential global health emergencies.
"This framework is designed to ensure that when a nation provides its samples, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to create them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage continued discussions with our US partners on how subsequent collaboration could be designed in a way that respects the sovereignty and dignity of both nations."
Medical Community Reaction
A leading public health body stated it acknowledged the official position, but suggested that talks must proceed since much of the nation's Aids initiatives relied on external financing.
"Where specific concerns arise, including those involving data governance or agreement terms, these can often be addressed via technical clarification and mutually agreed protections," the group added.
The situation highlights the continuing debate between accepting crucial international aid and protecting national sovereignty in an increasingly interconnected world.